Chemclin Diagnostics Co., Ltd. (SHA:688468)
China · Delayed Price · Currency is CNY 6.16
-0.01 (-0.16%)
Aug 4, 2026, 3:00 PM CST
Chemclin Diagnostics Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,431 | 2,896 | 2,703 | 4,327 | 3,797 | 7,186 | |
Market Cap Growth | -27.44% | 7.15% | -37.53% | 13.94% | -47.15% | - |
Enterprise Value | 2,275 | 2,276 | 2,063 | 3,602 | 2,822 | 6,305 |
Last Close Price | 6.16 | 7.34 | 6.73 | 10.41 | 8.86 | 16.55 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 67.55 | 65.96 | 21.27 | 29.36 | 24.88 | 50.34 |
PS Ratio | 7.49 | 8.71 | 6.20 | 9.72 | 8.16 | 15.26 |
PB Ratio | 1.71 | 2.05 | 1.91 | 3.12 | 2.75 | 5.62 |
P/TBV Ratio | 1.97 | 2.37 | 2.21 | 3.60 | 3.13 | 6.47 |
P/FCF Ratio | 39.20 | 120.62 | 44.71 | - | 31.84 | 61.78 |
P/OCF Ratio | 23.57 | 30.85 | 16.09 | 25.00 | 15.53 | 38.05 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 7.00 | 6.84 | 4.73 | 8.09 | 6.07 | 13.39 |
EV/EBITDA Ratio | 27.53 | 29.21 | 13.40 | 21.34 | 16.11 | 35.03 |
EV/EBIT Ratio | 86.82 | 73.08 | 19.17 | 27.37 | 20.89 | 45.98 |
EV/FCF Ratio | 36.68 | 94.78 | 34.13 | - | 23.66 | 54.21 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.16 | 0.16 | 0.18 | 0.17 | 0.01 | 0.02 |
Debt / EBITDA Ratio | 2.82 | 2.65 | 1.55 | 1.30 | 0.07 | 0.13 |
Debt / FCF Ratio | 3.75 | 9.66 | 4.13 | - | 0.11 | 0.21 |
Net Debt / Equity Ratio | -0.11 | -0.27 | -0.47 | -0.49 | -0.70 | -0.70 |
Net Debt / EBITDA Ratio | -2.14 | -4.92 | -4.28 | -4.05 | -5.55 | -5.00 |
Net Debt / FCF Ratio | -2.52 | -15.96 | -10.91 | 5.33 | -8.15 | -7.74 |
Asset Turnover | 0.18 | 0.19 | 0.24 | 0.26 | 0.31 | 0.39 |
Inventory Turnover | 1.09 | 1.09 | 1.05 | 0.99 | 1.03 | 1.08 |
Quick Ratio | 2.58 | 4.07 | 5.21 | 4.90 | 5.18 | 7.92 |
Current Ratio | 4.77 | 4.77 | 5.82 | 5.68 | 5.91 | 8.98 |
Return on Equity (ROE) | 2.69% | 3.11% | 9.06% | 10.64% | 11.48% | 13.18% |
Return on Assets (ROA) | 0.92% | 1.08% | 3.68% | 4.82% | 5.59% | 7.03% |
Return on Invested Capital (ROIC) | 1.91% | 3.08% | 13.57% | 20.99% | 29.56% | 33.87% |
Return on Capital Employed (ROCE) | 1.60% | 1.90% | 6.50% | 8.10% | 9.70% | 10.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 1.58% | 1.52% | 4.70% | 3.41% | 4.02% | 1.99% |
FCF Yield | 2.55% | 0.83% | 2.24% | -2.97% | 3.14% | 1.62% |
Dividend Yield | 2.03% | - | 1.86% | 1.20% | 3.91% | 1.03% |
Payout Ratio | 142.24% | 124.76% | 41.93% | 94.42% | 44.66% | - |
Buyback Yield / Dilution | -7.22% | -0.53% | 0.30% | 0.83% | -4.10% | -8.80% |
Total Shareholder Return | -5.19% | -0.53% | 2.16% | 2.03% | -0.18% | -7.78% |